Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the
“Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing and nucleic acid-based technologies, announced that
safeCircle™, its high-throughput, pooled COVID-19 testing program,
has been implemented at Sarah Lawrence College (the “College”) as
an addition to the College’s in-house testing practice to monitor
for the prevalence of COVID-19 during the College’s Fall 2021
semester. Testing began this week and is available to asymptomatic
students, faculty, and staff on a voluntary basis. The College’s
population of approximately 2,000 undergraduate and graduate
students, faculty, and staff are required to be vaccinated against
COVID-19.
Mary Hartnett, Director of Medical Services at Sarah Lawrence
College, stated, “safeCircle was our choice given the convenience
of its on-site sample collection process, access to
high-sensitivity RT-PCR-based testing with rapid turnaround times,
ability to scale with our needs, and capacity to ease our
administrative burdens. We see safeCircle as a complement to our
vaccine mandate.”
Mike Munzer, executive director of Diagnostic Sales at Applied
DNA, said, “The increased transmissibility of the Delta variant, as
well as the variant’s capacity to reduce the effectiveness of
vaccines against infection, we believe, makes all the more
compelling the need to test both vaccinated and unvaccinated
populations. safeCircle’s approach to COVID-19 testing, the
combination of a comprehensive managed services offering and
self-service reporting and communications platform provided by our
partner, CLEARED4, continues to resonate with institutes of higher
education seeking to keep populations safe and campuses open. We
applaud Sarah Lawrence College for making testing broadly available
on its campus to asymptomatic employees and students.”
About safeCircle™
safeCircle is a turnkey testing solution that provides for all
aspects of large population COVID-19 testing – from sample
collection to results reporting – for institutes of higher
education, K-12 schools, businesses, and healthcare facilities,
among other institutions with large populations. safeCircle
utilizes frequent, high-sensitivity pooled RT-PCR testing to help
prevent virus spread by quickly identifying infections within a
community, school, or workplace. Testing is conducted utilizing
Applied DNA’S Linea™ COVID-19 Assay Kit that provides rapid results
using real-time PCR (RT-PCR testing) with results returned
typically within 24 to 48 hours at Applied DNA’s CLEP-permitted,
CLIA-certified laboratory.
Click through to learn more about how safeCircle can help your
community, school, and workplace:
https://adnas.com/safecircle-college-safety/
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary,
large-scale polymerase chain reaction (“PCR”)-based manufacturing
platform that allows for the large-scale production of specific DNA
sequences.
The LinearDNA platform has utility in the nucleic acid-based in
vitro diagnostics and preclinical nucleic acid-based drug
development and manufacturing market. The platform is used to
manufacture DNA for customers as components of in vitro diagnostic
tests and for preclinical nucleic acid-based drug development in
the fields of adoptive cell therapies (CAR T and TCR therapies),
DNA vaccines (anti-viral and cancer), RNA therapies, clustered
regularly interspaced short palindromic repeats (CRISPR) based
therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such
as supply chain security, anti-counterfeiting and anti-theft
technology. Key end-markets include textiles, pharmaceuticals and
nutraceuticals, and cannabis, among others.
Leveraging its deep expertise in nucleic acid-based
technologies, the Company has also established safeCircle™, a
pooled COVID-19 testing program that is grounded in the Company’s
EUA-authorized Linea™ COVID-19 Assay Kit. safeCircle is designed to
look for infection within defined populations or communities
utilizing pooled testing methodologies that increase testing
efficiencies. The Company has also developed and intends to seek
EUA-authorization for its Linea™ SARS-CoV-2 Mutation Panel, an
assay-based panel for the detection of certain SARS-CoV-2 genetic
mutations.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under the ticker
symbol ‘APDN,’ and its publicly traded warrants are listed on the
OTCexchange under the ticker symbol ‘APPDW.’
Applied DNA is a member of the Russell Microcap® Index.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
"forward-looking" in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA's future
plans, projections, strategies, and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to its history of
net losses, limited financial resources, limited market acceptance
(including for our COVID-19 diagnostic and other testing
offerings), the unknown amount of revenues and profits that will
result from our safeCircle COVID-19 testing contracts, the
possibility that the Linea Assay Kit could become obsolete or have
its utility diminished, the uncertainties inherent in research and
development, future clinical data and analysis, including whether
any of Applied DNA's or its partner's diagnostic candidates will
advance further in the preclinical research or clinical trial
process, including receiving clearance from the U.S. Food and Drug
Administration (U.S. FDA) or equivalent foreign regulatory agencies
to conduct clinical trials and whether and when, if at all, they
will receive final approval from the U.S. FDA or equivalent foreign
regulatory agencies, the unknown outcome of any applications or
requests to U.S. FDA, equivalent foreign regulatory agencies and/or
the New York State Department of Health, the unknown limited
duration of any Emergency Use Authorization (EUA) approval from
U.S. FDA, changes in guidance promulgated by the CDC, U.S. FDA
and/or CMS relating to COVID-19 testing, disruptions in the supply
of raw materials and supplies, and various other factors detailed
from time to time in Applied DNA's SEC reports and filings,
including our Annual Report on Form 10-K filed on December 17,
2020, and Quarterly Reports on Form 10-Q filed on February 11,
2021, May 13, 2021 and August 12, 2021, and other reports we file
with the SEC, which are available at www.sec.gov. Applied DNA
undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events unless otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211012005773/en/
For Applied DNA: Investor Contact: Sanjay M.
Hurry, 917-733-5573, sanjay.hurry@adnas.com Program Contact:
Mike Munzer, 631-240-8814, mike.munzer@adnas.com Web:
www.adnas.com Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024